NCT04196985 (HENEPET) is a NA clinical trial of PET/MRI in Head and Neck Squamous Cell Carcinoma, sponsored by Turku University Hospital.

Who is sponsoring NCT04196985?

NCT04196985 is sponsored by Turku University Hospital.

What drugs are being tested in NCT04196985?

Interventions in NCT04196985: PET/MRI, PET/CT.

What condition does NCT04196985 study?

NCT04196985 studies Head and Neck Squamous Cell Carcinoma.

Is NCT04196985 still recruiting?

NCT04196985 is currently status unknown. Last updated 13 April 2021.

Last reviewed 2021-04-13 · How we verify

NCT04196985: HENEPET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC

Status unknown NA Last updated 13 April 2021

What this trial tests

NA trial testing PET/MRI in Head and Neck Squamous Cell Carcinoma in 40 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
1 October 2022

1 October 2024

Quick facts

Lead sponsor	Turku University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	1 October 2020
Primary completion	1 October 2022
Estimated completion	1 October 2024
Sites	1 location across Finland

Drugs / interventions tested

PET/MRI
PET/CT

Conditions studied

Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →

Sponsor

Turku University Hospital

Who can join

18 and older, any sex, with Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparing FDG PET/CT and FDG PET/MRI in the diagnostic accuracy of detecting local recurrence 12 weeks after the end of CRT in head and neck squamous cell carcinoma patients. Forty patients aged more than 18 years who have a histologically confirmed HNSCC and have received chemoradiation therapy will be recruited for the study. The patients will be scanned with both PET/CT and PET/MRI 12 weeks after the end of CRT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Diagnostic Accuracy of <sup>18</sup>F-FDG-PET/CT and <sup>18</sup>F-FDG-PET/MRI in Detecting Locoregional Recurrence of HNSCC 12 Weeks after the End of Chemoradiotherapy: Single-Center Experience with PET/MRI.
Murtojärvi S, Malaspina S, Kinnunen I, Tuokkola T, et al · · 2022 · cited 5× · PMID 36082064 · DOI 10.1155/2022/8676787

Verify or expand the search:

Other trials of PET/MRI

Trials testing the same drug.

NCT07523997 — Imaging of Endometriosis With Total-body PET-CT (PET-Endo) · not yet recruiting
NCT07010484 — Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica · recruiting
NCT06947759 — Application of 18F-FDG PET/MRI for Initial Staging in Locally Advanced Nasopharyngeal Carcinoma · not yet recruiting
NCT05954507 — Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis · NA · recruiting
NCT06856096 — PET/MRI Artificial Intelligence Reconstruction Algorithm AIR Recon DL Image Quality Evaluation and Clinical Study · NA · active not recruiting

Other recruiting trials for Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting

Other Turku University Hospital trials

Trials by the same sponsor.

NCT07488494 — Effective Implementation of the Physical Activity and Motor Skills Intervention for 3-6-year-old Children With Cancer (E · NA · not yet recruiting
NCT07316868 — Neuroprotective Effect of Mild Hypothermia Versus Normothermia During Cardiopulmonary Bypass of Coronary Artery Surgery · NA · not yet recruiting
NCT07306000 — Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development · NA · recruiting
NCT07272824 — Usability Study of Gestational and Postpartum Weight Management Program · recruiting
NCT07310472 — Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04196985 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Turku University Hospital
Last refreshed: 13 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04196985.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing